Research programme: anti-cytokine monoclonal antibodies - XBiotech

Drug Profile

Research programme: anti-cytokine monoclonal antibodies - XBiotech

Alternative Names: X071NAB; X072NAB; X081NAB; X082NAB; X083NAB

Latest Information Update: 23 Nov 2016

Price : $50

At a glance

  • Originator XBiotech
  • Developer Brigham and Women's Hospital; Massachusetts General Hospital; XBiotech
  • Class Monoclonal antibodies
  • Mechanism of Action Cytokine inhibitors; Immunomodulators; Interleukin 1 alpha inhibitors; Interleukin 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Crohn's disease; Inflammatory bowel diseases; Myocardial reperfusion injury
  • No development reported Arthritis; Chronic obstructive pulmonary disease; Coronary artery restenosis; Hypereosinophilic syndrome; Inflammation; Multiple myeloma; Psoriasis; Reperfusion injury; Systemic lupus erythematosus; Type 1 diabetes mellitus; Uveitis

Most Recent Events

  • 17 Nov 2016 XBiotech and Case Western Reserve University School of Medicine collaborate to develop novel therapeutics for Inflammatory Bowel Disease
  • 16 Jul 2016 No recent reports of development identified for research development in Arthritis in USA (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for research development in Chronic-obstructive-pulmonary-disease in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top